Understand the source comparison
AICAR vs MOTS-c
MOTS-c is a 16-amino acid mitochondrial-derived peptide that also activates AMPK. Unlike AICAR, MOTS-c is an actual peptide, encoded by mitochondrial DNA and naturally produced in response to exercise. The activation pathway differs. MOTS-c works through the f
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- MOTS-c is a 16-amino acid mitochondrial-derived peptide that also activates AMPK. Unlike AICAR, MOTS-c is an actual peptide, encoded by mitochondrial DNA and naturally produced in response to exercise.
- The activation pathway differs. MOTS-c works through the folate-AICAR-AMPK pathway, interestingly using endogenous AICAR accumulation as an intermediate step. MOTS-c inhibits the folate cycle, which reduces purine biosynthesis, causing AICAR (the endogenous intermediate) to accumulate and activate AMPK.
- MOTS-c has additional capabilities beyond AMPK activation. Under metabolic stress, it translocates to the cell nucleus and interacts with transcription factors including NRF2, directly influencing gene expression. This nuclear function gives MOTS-c a dimension that exogenous AICAR lacks.
- Research shows MOTS-c treatment increased healthspan and lifespan in aged mice, with a 6.4% increase in median lifespan when treatment began at the equivalent of 70 human years. AICAR has not been tested in comparable longevity studies.
- For researchers choosing between these compounds, MOTS-c offers a more physiological approach since it is a naturally occurring molecule. AICAR provides more direct AMPK activation and has substantially more published research data. The MOTS-c safety profile includes different considerations than AICAR, particularly regarding injection site reactions and metabolic adaptation periods.